> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-140/
- Published: 2017-07-16T12:00:00.000Z
- Updated: 2026-09-14T22:34:27.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139145

[**Draft Guidances for ANDA Bioequivalence Study Designs**](https://www.fdaweb.com/draft-guidances-for-anda-bioequivalence-study-designs/)  
*Federal Register* notice: FDA announces the availability of additional draft and revised draft product-specific guidances that provide product-specific recommendations on bioequivalence study designs. 07/14/2017

[**2 Animal Drugs Withdrawn on Sponsor’s Request**](https://www.fdaweb.com/2-animal-drugs-withdrawn-on-sponsors-request/)  
*Federal Register* notice: FDA withdraws approval of two new animal drug applications at the sponsor’s request because these products are no longer manufactured or marketed. 07/12/2017

[**Comments Sought on Drug CMC Date Elements**](https://www.fdaweb.com/comments-sought-on-drug-cmc-date-elements/)  
*Federal Register* notice: FDA requests comment on draft standardized Pharmaceutical Quality/Chemistry Manufacturing and Control data elements and terminologies for electronic submission. 07/11/2017

[**Regulatory Review Period Determination for Intercept Plasma Device**](https://www.fdaweb.com/regulatory-review-period-determination-for-intercept-plasma-device/)  
*Federal Register* notice: FDA determines that the regulatory review period for Cerus Corp.’s Intercept Blood System For Plasma is 6,497 days. 07/11/2017

[**Regulatory Review Period Determination for Intercept Platelet Device**](https://www.fdaweb.com/regulatory-review-period-determination-for-intercept-platelet-device/)  
*Federal Register* notice: FDA determines that the regulatory review period for Cerus Corp.’s Intercept Blood System for Platelets is 7,080 days. 07/11/2017

[**1,003 Class 2 Devices Exempted from 510(k)**](https://www.fdaweb.com/1-003-class-2-devices-exempted-from-510-k/)  
*Federal Register* notice: FDA announces a list of 1,003 Class 2 devices that it has determined no longer require premarket notification to provide reasonable assurance of safety and effectiveness. 07/11/2017

[**Panel to Review Expanded Use for Pfizer’s Xeljanz**](https://www.fdaweb.com/panel-to-review-expanded-use-for-pfizers-xeljanz/)  
*Federal Register* notice: FDA announces an 8/3 Arthritis Advisory Committee meeting that will review a Pfizer supplemental NDA for Xeljanz (tofacitinib) for treating adult patients with active psoriatic arthritis. 07/10/2017

[**FDA Files Annual Reports on Closed Panel Meetings**](https://www.fdaweb.com/fda-files-annual-reports-on-closed-panel-meetings/)  
*Federal Register* notice: FDA files with the Library of Congress annual reports of certain FDA advisory committees that held closed meetings during fiscal year 2016\. 07/10/2017

[**Approved Information Collection Listing**](https://www.fdaweb.com/approved-information-collection-listing/)  
*Federal Register* notice: FDA publishes a list of information collections that have been approved by the Office of Management and Budget. 07/10/2017

[**Comments Sought on Safety Communication Surveys**](https://www.fdaweb.com/comments-sought-on-safety-communication-surveys/)  
*Federal Register* notice: FDA seeks comments on an information collection on “FDA Safety Communication Readership Surveys.” 07/10/2017